Table 2.
Geometric mean (95% CI) atazanavir and ritonavir pharmacokinetics sorted by CYP3A5 expressor status
| CYP3A5 expressors (n = 15) | Non-expressors (n = 16) | P | |
|---|---|---|---|
| Atazanavir alone day 7 | |||
| CL/F (L/h/kg)a | 0.25 (0.20–0.30) | 0.18 (0.15–0.22) | 0.045 |
| t1/2 (h) | 5.89 (4.95–7.01) | 7.54 (6.18–9.21) | 0.057 |
| AUCtau (h*ng/mL) | 22 151 (17 996–27 265) | 27 400 (22 407–33 504) | 0.15 |
| Cmax (ng/mL) | 3652 (2995–4453) | 4430 (3655–5368) | 0.16 |
| Cmin (ng/mL) | 87 (55–140) | 171 (109–270) | 0.044 |
| day 3 trough (ng/mL) | 108 (59–199) | 194 (92–410) | 0.21 |
| CYP3A5 expressors (n = 14) | Non-expressors (n = 12) | P | |
| Atazanavir (plus ritonavir) day 14 | |||
| CL/F (L/h/kg) | 0.09 (0.07–0.11) | 0.07 (0.06–0.09) | 0.15 |
| t1/2 (h) | 10.4 (8.5–12.8) | 13.5 (8.9–20.4) | 0.22 |
| AUCtau (h*ng/mL) | 46 022 (38 085–55 613) | 49 598 (40 426–60 850) | 0.58 |
| Cmax (ng/mL) | 4609 (4051–5244) | 4883 (4248–5613) | 0.54 |
| Cmin (ng/mL) | 605 (406–900) | 722 (470–1109) | 0.54 |
| day 10 trough (ng/mL) | 870 (537–1411) | 1159 (870–1544) | 0.30 |
| Ritonavir | |||
| CL/F (L/h/kg) | 0.12 (0.09–0.16) | 0.13 (0.09–0.17) | 0.75 |
| t1/2 (h) | 4.05 (3.48–4.71) | 4.54 (3.83–5.38) | 0.28 |
| AUCtau (h*ng/mL) | 11 706 (8657–15 832) | 11 580 (8757–15 313) | 0.95 |
| Cmax (ng/mL) | 1717 (1329–2220) | 1648 (1249–2176) | 0.82 |
| Cmin (ng/mL) | 34 (21–55) | 42 (30–58) | 0.49 |
Bold formatting indicates significant values.
aPrimary endpoint.